Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04042402 · ClinicalTrials.gov registry record · Phase 3
Long Term Extension Study in Patients With Primary Hyperoxaluria
A Phase 3 study of Kidney Diseases and Genetic Disease, sponsored by Dicerna Pharmaceuticals, Inc., a Novo Nordisk company.
- Active
- Registry status
- Phase 3
- Development phase
- 75
- Enrollment target
- 20
- Study locations
NCT04042402 is a Phase 3 study of Kidney Diseases and Genetic Disease that is active but no longer recruiting, run by Dicerna Pharmaceuticals, Inc., a Novo Nordisk company. The registered enrollment target is 75 participants, below the 1,784-participant average among 38 other Kidney Diseases trials with a reported enrollment target (96% lower). The trial reports 20 study locations across 7 states.
The verdict
NCT04042402, a Phase 3 study of Kidney Diseases and Genetic Disease, is active but no longer recruiting, sponsored by Dicerna Pharmaceuticals, Inc., a Novo Nordisk company.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 75 participants
- Enrollment target
- 20
- Study locations
Study Summary
The proposed study is designed to provide patients previously enrolled in Phase 1 and 2 studies of DCR-PHXC and their siblings (\<18 years old) long-term access to DCR-PHXC, and to evaluate the long-term safety and efficacy of DCR-PHXC in patients with PH.
Conditions Studied
Interventions
- DRUG DCR-PHXC
Study Locations (20)
Other
- Clinical Trial Site - Melbourne
- Clinical Trial Site - Bron
- Clinical Trial Site - Paris
- Clinical Trial Site - Bonn
- Clinical Trial Site - Heidelberg
- Clinical Research Site - Roma
- Clinical Trial Site - Fukuoka
- Clinical Trial Site - Nagoya
- Clinical Trial Site - Tokyo
- Clinical Trial Site - Beirut
- Clinical Trial Site - Amsterdam
- Clinical Trial Site - Tromsø
- Clinical Research Site - Barcelona
- Clinical Trial Site - Barcelona
California
- Clinical Research Site - San Francisco
Massachusetts
- Clinical Trial Site - Boston
Minnesota
- Clinical Trial Site - Rochester
New York
- Clinical Trial Site - New York
Queensland
- Clinical Research Site - Herston
Ontario
- Clinical Research Site - Hamilton
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 75 participants |
| Start Date | 2019-07-09 |
| Est. Completion | 2030-04-01 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04042402
The ClinicalTrials.gov registry entry for NCT04042402 describes a study currently listed as active not recruiting, categorized as Phase 3. The registered enrollment target is 75 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,784-participant average among 38 other Kidney Diseases trials with a reported enrollment target (96% lower). The listed sponsor is Dicerna Pharmaceuticals, Inc., a Novo Nordisk company, which has 13 total studies on file at ClinicalTrials.gov.
The record links to 6 conditions, with Kidney Diseases appearing as the primary indexed condition, and to 1 intervention - of which DCR-PHXC is the first listed.
NCT04042402 reports 20 study locations spanning 7 distinct geographic areas - top geographies include Other, California, Massachusetts.
Frequently Asked Questions
What is clinical trial NCT04042402 about?
NCT04042402 is a clinical study titled "Long Term Extension Study in Patients With Primary Hyperoxaluria". The proposed study is designed to provide patients previously enrolled in Phase 1 and 2 studies of DCR-PHXC and their siblings (\<18 years old) long-term access to DCR-PHXC, and to evaluate the long-term safety and efficacy of DCR-PHXC in patients with PH.
What is the current status of trial NCT04042402?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 75 participants. The study started on 2019-07-09. Estimated completion is 2030-04-01.
What conditions does trial NCT04042402 study?
This clinical trial studies the following conditions: Kidney Diseases, Genetic Disease, Urologic Diseases, Primary Hyperoxaluria Type 1 (PH1), Primary Hyperoxaluria Type 2 (PH2).
What interventions are being tested in trial NCT04042402?
The interventions under investigation include: DCR-PHXC (DRUG).
Who is sponsoring clinical trial NCT04042402?
This trial is sponsored by Dicerna Pharmaceuticals, Inc., a Novo Nordisk company, which has 13 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04042402 being conducted?
This trial has 20 study locations across California, Massachusetts, Minnesota, New York, Queensland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Kidney Diseases
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Kidney Transplant Preemptive Therapy or Prophylaxis for CMV Prevention in D+R Recipients
RECRUITING · Phase 3
-
Open-label Extension Study of Zigakibart in Adults With IgA Nephropathy.
RECRUITING · Phase 3
-
Savolitinib vs. Sunitinib in MET-driven PRCC.
ACTIVE NOT RECRUITING · Phase 3
-
Study of MB-102 (Relmapirazin) and the Use of the MediBeacon® Transdermal GFR Measurement System Using the TGFR Reusable Sensor With Disposable Adhesive Ring
COMPLETED · Phase 3
-
Collaborative Learning to Achieve Refined Interventions for Emory: Kidney Disease
RECRUITING · NA
-
Rutgers University Study of the Genetics of Kidney Disease
RECRUITING
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.